子宫内膜癌的发展趋势:一个研究所40年的经验
Masayuki Yamaguchi1, Naohisa Kushiya1, Ryo Tamura1
1Department of Gynecology, Niigata Cancer Center Hospital, Niigata 951-8566, Japan.
Japanese journal of clinical oncology
|February 9, 2024
概括
在日本,子宫内膜癌的预后有所恶化,可能是由于非子宫内膜癌亚型 (如血清性和混合性癌症) 的增加. 进一步监测至关重要,以确认这一趋势在全国范围内.
科学领域:
- 妇科 妇科医生 妇科
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 在日本,子宫内膜癌的预后趋势尚未完全理解.
- 分析长期数据对于评估患者治疗结果的变化至关重要.
研究的目的:
- 评估目前在日本的子宫内膜癌的预后.
- 在一个机构分析子宫内膜癌患者的长期趋势.
主要方法:
- 分析了1984年至2022年间被诊断患有子宫内膜癌的1463名患者.
- 患者被分为五个基于时间的组 (1984-1991,1992-1999,2000-2006,2007-2014,2015-2022).
- 统计分析包括Jonckheere-Terpstra测试,Cochran-Armitage测试和Cox回归分析.
主要成果:
- 多变量分析表明2000-2006年组的预后最差 (HR1.88).
- 随着时间的推移,非子宫内膜腺癌的发病率,特别是血清性和混合类型,显著增加.
- 非子宫内膜腺癌,血清癌和混合癌的比例分别从2007年至2014年的19.0%,5.5%和3.1%上升到28.2%,10.8%和4.6% (2015-2022年).
结论:
- 非子宫内膜瘤子宫内膜癌的发病率增加,特别是血清性和混合型,可能与预后恶化相关.
- 需要持续监测,以确定这种趋势是否在日本普遍存在.
- 这些发现凸显了更新治疗策略和对子宫内膜癌亚型的监测的需要.
更多相关视频
05:16Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
3.4K
07:44Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
Published on: February 17, 2023
1.5K
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:21Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346